49 results about "Tumour development" patented technology

The present disclosure concerns LNA oligonucleotides having a (sub)sequence of the general formula 5′-(MeCx)(Tx)MeCxAsAstscscsastsgsgsMeCxAx(Gx)(c)-3′, and preferably of the general formula 5′-MeCxTxMeCxAsastscscsastsgsgsMeCxAxGxc-3′, wherein capital letters designate an LNA nucleotide analogue selected from β-D-oxy-LNA, β-D-thio-LNA, β-D-amino-LNA and α-L-oxy-LNA, small letters designate a deoxynucleotide, and underline designates either an LNA nucleotide analogue as defined above or a deoxynucleotide. Such LNA oligonucleotides exhibit surprisingly good properties with respect to inhibition of the expression of Survivin by means of an anti-sense mechanism, and thereby lead to reduction or inhibition of tumour development in vivo. The LNA oligonucleotides are superior to other LNA oligonucletides targeting Surviving mRNA measured by functional read outs such as apoptosis induction and proliferation inhibition, and is potent in down-regulating Survivin mRNA and protein in transfected cancer cell lines, and induce apoptosis in combination with Taxol superior compared to other LNA oligonucleotides.

The invention provides a breast cancer circulating tumor cell line CTC-3, a culture medium, and a building method and application of the CTC-3, and relates to the technical field of cells. The collection number of the breast cancer circulating tumor cell line CTC-3 provided by the invention is CCTCC NO: C201892. The character of the cell line is stable, and large-scale basic researches and clinical tests can be developed, thereby further mastering features of a circulating tumor cell and explaining a tumor development mechanism, and providing a basis for clinical staging, prognosis and individualized treatment for a cancer patient. The culture medium provided by the invention comprises a basic culture medium and an additive. The culture medium can greatly multiply high-quality and high-purity circulating tumor cells. The building method of the breast cancer circulating tumor cell line CTC-3 is easy to operate, low in cost and wide in universality, and can quickly and effectively realize multiplication culture of the breast cancer circulating tumor cells.

The invention provides a drug-loaded liposome which comprises long-circulating liposome and pharmaceutically active ingredients wrapped in the long-circulating liposome, wherein the pharmaceutically active ingredients comprise paclitaxel and resveratrol. The invention further provides a preparation method of the drug-loaded liposome. The method comprises, by using a thin film-ultrasonic method, preparing liposome sources, distearoyl phosphatidyl ethanolamine-methoxy polyethylene glycol 2000 and the pharmaceutically active ingredients into the drug-loaded liposome, wherein the pharmaceutically active ingredients comprise the paclitaxel and the resveratrol. The invention further provides the drug-loaded liposome prepared by the invention. In addition, the invention provides an application of the liposome in preparing antitumor drug and in treating the tumor. The drug-loaded liposome contains the paclitaxel and the resveratrol, has activity of inhibiting development of drug-sensitive tumor, furthermore effectively inhibits development of chemotherapeutic-drug-resistance tumor, and has great clinical value.

The invention discloses a multi-targeting antitumor composite preparation and a preparation method thereof. The multi-targeting antitumor composite preparation comprises a Fu vesicle suspension, DOX-BSA and FA-DOX. A vesicle administration system is prepared through integrating immunotherapy, positive targeting chemotherapy medicine drug molecules and a passive targeting administration system realize in order to realize low toxicity and high efficiency treatment of tumors, and the vesicle administration system can obviously slowly release Fu to effectively containment tumor development and has small influences on tumor bearing bodies; a newly synthesized immunogen can obtain an antibody with high sensitivity, so foundation is laid for formation of an immune compound macromolecule required by immunotherapy; and the micro-molecular compound FA-DOX has a molecule bridging effect in immunotherapy to promote formation of the immune compound macromolecule. The composite preparation has obviously better curative effects than simple particle administration chemical treatment or simple immunotherapy, has obviously low toxicity, can improve the antitumor effect, and is an anticancer composite preparation with wide research and application prospect.

The invention discloses a novel tumor marker GSTA1 for lung cancer as well as a screening method and application thereof, belonging to the field of molecular biology and medical science. The marker is characterized in that on the basis of the novel lung cancer specific binding polypeptide acquired by utilizing a bacteriophage random peptide library screening technology at the earlier stage, the polypeptide is used as a probe to select lung cancer associated antigen GSTA1 from a lung cancer cDNA library. The occurrence and development of the lung cancer have a complicated mechanism, the lung cancer involves to the alteration of a lot of lung cancer associated genes and expressions thereof in the primary stage, a plurality of adhesion molecules as well as receptors or ligands can be expressed in a patient body under the effect of a carcinogenic factor, the content of the marker released by the tumor at different development stages is also different, the variation of the specific molecular marker of the tumor cancer is detected from peripheral blood and sputum, advantages of simplicity, rapidness, little pain and easiness in reviewing can be achieved, the novel tumor marker GSTA1 is easy to receive by the patient, and an important significance on the clinical diagnosis for the lung cancer can be achieved. The molecular marker can be provided for the diagnosis and targeted therapy of the lung cancer, a candidate antigen can be provided for the research of the lung cancer tumor vaccine, and the application prospect is wide.

The present invention includes a diagnostic assay for the detection and determination of MGP in a human serum sample, which comprises the use of one or more antibodies, preferably monoclonal antibodies, specifically recognizing epitopes on and / or conformations of human Matrix Gla-Protein. A method is provided for using MGP-related antigens as biomarkers for certain diseases, for example, atherosclerosis and other vascular diseases, and angiogenesis / neogenesis in tumor development. Monoclonal antibodies of class IgG are described for use in the assay, which are defined herein as mAb3-15, mAb35-49[Glu], mAb35-49[Gla], mAb35-53[Glu], and mAb35-53[Gla]. Polyclonal antibodies and methods are also disclosed for measuring MGP in a human serum sample.

Hepatocyte growth factor / scatter factor (HGF / SF), acting through the Met receptor, plays an important role in most human solid tumors and inappropriate expression of this ligand-receptor pair is often associated with poor prognosis. The molecular basis for the malignant activity imparted by signaling of HGF / SF-Met in cancer cells has been attributed to its mitogenic and invasive properties. However, HGF / SF also induces angiogenesis, but the signaling mechanism has not been understood, nor has this activity been directly associated with HGF / SF-Met mediated tumorigenesis. HGF / SF induces expression in vitro of VEGF, a key agonist of tumor angiogenesis. By contrast, thrombospondin-1 (TSP-1) is a negative regulator of angiogenesis. This application discloses that, in the very same tumor cells, in addition to inducing VEGF expression, HGF / SF dramatically down regulates TSP-1 expression. TSP shut off plays an important, extrinsic role in HGF / SF-mediated tumor development, as ectopic expression of TSP-1 markedly inhibited tumor formation through the suppression of angiogenesis. While VEGF induced expression is sensitive to inhibitors of several pathways, including MAP kinase, PI3 kinase and Stat3, TSP-1 shut off by HGF / SF is prevented solely by inhibiting MAP kinase activation. Thus HGF / SF is a “switch” for turning on angiogenesis. TSP-1 is a useful antagonist to tumor angiogenesis, and therefore TSP-1 and agonist peptides and mimics, as well as inducers of TSP-1, have therapeutic value when used in conjunction with inhibitors of VEGF.

The present invention relates to targets of loss of imprinting (LOI) affected IGF2 gene products in pre-malignant tissues, where methods of inhibiting those targets, including IGFR1, are disclosed to prevent tumor development in subjects at risk for developing colorectal cancer (CRC). The present invention also relates to methods of identifying increased risk in developing CRC in a subject, including methods of assessing the efficacy of a chemotherapeutic regimen. Further, the present invention relates to methods for identifying anti-neoplastic agents.

The invention relates to the field of biotherapy, and especially relates to a tumor cell vaccine and a preparation method thereof. According to the invention, molecule in-vitro modified tumor cells can indentified by using antigen presenting cells, the modified tumor cell vaccine can be identified by the antigen presenting cell in vivo, and then is subjected to phagocytosis; an endocytosed tumor cell content (comprising tumour-related antigen molecule and neoantigenic peptide) is processed by the antigen presenting cell, and then is presented or shown on the surface of the cell, then the corresponding immunization effect cell can be activated, an integral reaction of an immunization system starts, and purposes of restricting tumour development and treating tumour can be reached. The methodhas the advantages of simple preparation, low cost, and short preparation period, and provides the novel and effective tumor vaccine.

The invention features tumor antigens; tumor antigen-encoding nucleic acids; antibodies specific for tumor antigens and methods of using the antibodies; methods of identifying tumor antigens and the nucleic acids that encode them; methods of monitoring or diagnosing tumors in patients; methods of testing patients for the increased likelihood of developing a tumor; and methods and compositions for treatment of a tumor or prophylaxis against developing a tumor.

Cancer-testis antigens were simultaneously packaged with CpG adjuvant and incorporated into an E2 nanoparticle platform to increase cancer vaccine efficacy. Also described herein is a combination of checkpoint blockade therapy and the nanoparticle vaccine platform to deliver cancer antigens with adjuvant for treatment of tumors and prevention of future tumors. The nanoparticle vaccine platform includes a protein capsule to which are attached adjuvants in the internal hollow cavity and cancer epitopes to the surface. Whereas single-therapies only increase survival, the combined therapy can both increase survival time as well as prevent tumor development in pre-existing tumor conditions by increasing tumor antigen-specific responses (via the nanoparticle vaccines) while simultaneously blocking checkpoints to remove immune suppression (via immune checkpoint inhibition). Furthermore, tumor re-challenge studies show evidence of T cell memory which can prevent tumor development in some individuals.

The present disclosure concerns LNA oligonucleotides having a (sub)sequence of the general formula 5'- ( Me Cx )(Tx,) Me CXAs Astscscsastsgsgs MeCXAX (G x) (c)-3',and preferably of the general formula 5'- Me C XTX), MeCXAsastscscsastsgsgs Me CxAx G x c-3', wherein capital letters designate a n LNA nucleotide analogue selected from .beta. -D-oxy-LNA, .beta. -D-thio-LNA, .beta.-D-amino-LNA and a-L-oxy-LNA, small letters designate a deoxynucleotid e, and underline designates either an LNA nucleotide analogue as defined above or a deoxynucleotide. Such LNA oligonucleotides exhibit surprisingly good properties with respect to inhibition of the expression of Survivin by means of an anti-sense mechanism, and thereby lead to reduction or inhibition of tumour development in vivo. The LNA oligonucleotides are superior to other L NA oligonucletides targeting Surviving mRNA measured by functional read outs such as apoptosis induction and proliferation inhibition, and is potent in down- regulating Survivin mRNA and protein in transfected cancer cell lines, and induce apoptosis in combination with Taxol superior compared to other LNA oligonucleotides.

The invention provides compositions comprising IGFBP-4 and methods for inhibiting angiogenesis and tumor development processes, and for treating angiogenesis-dependent conditions, using an insulin growth factor binding protein, IGFBP-4.

The invention relates to the use of inhibitors of the expressed proteins of the murine genes and / or their human homologues listed in Table 1 for the preparation of a therapeutical composition for the treatment of cancer, in particular for the treatment of solid tumors of lung, colon, breast, prostate, ovarian, pancreas and leukemia and the use of the genes listed in Table 1 for the diagnosis of cancer. The invention also relates to the therapeutical compositions comprising the inhibitors and to methods for development of the inhibitor compounds.

The invention discloses a dithiocarbamate complex marked by a kind of 99TcmN nuclear with general formaul as 99TcmN (DTC) 2, which is blended by five dithiocarbamate complexes marked by 99TcmN (DTC)2 with 99TcmN(3M2BDTC)2, 99TcmN(DEDTC)2, 99TcmN(4MCHDTC)2, 99TcmN(NMCHDTC)2 and 99TcmN(CHDTC)2 according to freeze-drying method, wherein the complex has good external stability under indoor temperature with radioactive chemical purity over 90%, which can be tumour imaging agent with applying value in the nuclear medical and radioactive drug chemical domain. The invention can be widely applied in the development of human or animal organ tissue, especially for the application of tumour development.

The present invention relates to products and compositions containing (i) a chemotherapeutic agent and (ii) at least an active compound chosen from CCL2 inhibitors, CCR2 inhibitors, NF-κB inhibitors, PARP-1 inhibitors and ATM inhibitors, as a combined preparation for simultaneous, separate or sequential use for inhibiting tumor development caused by tumor cell senescence induced by said chemotherapeutic agent. The invention also refers to a method for monitoring the response to a chemotherapeutic agent of a patient suffering from a cancer, and to a method for predicting the tumor size evolution and / or the onset of metastasis in a patient suffering from a cancer.

Treatment of tumors, especially breast cancer or glioblastoma tumors, by silencing RAB27A and / or TRAF3IP2, compositions and methods for same.

Disclosed are methods for assessing tumor cell growth in a patient for the diagnosis, monitoring and / or staging of tumor development. The method include the identification of reduced cdk6 expression or biological activity as an indicator of increased cell growth in a cell sample. The methods further include the identification of compounds which regulate cdk6 and the use of such compounds in a method for the regulation of inappropriate cell growth.

5′-methylthioadenosine (MTA) is described as a compound that is susceptible to inhibiting and / or blocking the epithelial-mesenchymal transition (EMT), a process whereby epithelial cells become mesenchymal cells.The periodical intake of MTA [every 24 h for 21 days] significantly improves fibrosis and the markers for hepatic cellular damage in KO-Mdr2 mice with MTA (28 mg / kg). Following the daily oral administration of MTA, both the expression of EMT markers in the total liver and appreciable signs of fibrosis are significantly reduced, indicating the beneficial effect of MTA on the liver affected by the lack of Mdr2. MTA is proposed to be a safe drug, suitable for oral formulation and without secondary effects, to be used in the prevention and / or treatment of diseases associated with EMT, including chronic cholestatic diseases, fibrosis and cholangiocarcinoma. On the other hand, MTA is proposed for application in anti-tumor therapies by inhibiting or blocking the EMT properties of CSC cells, in order to improve the prognosis of tumor development and the malignancy thereof.

The invention belongs to the technical field of bioinformatics, and discloses a non-differential gene associated with tumor cell malignant phenotypes and a screening method and application thereof, the non-differential gene interacts with a plurality of differential genes of cancerous tissues, is ubiquitous in the cancerous tissues and para-carcinoma tissues, has relatively high abundance expression and no differential expression, and can be used for screening tumor cell malignant phenotypes. And the characteristic of playing a heavy role in a network path is realized. And sorting the genes to be distinguished through an SVM model for distinguishing cancerous tissues and para-carcinoma tissues, and removing differential genes from the genes at the first 5% of the sorted genes to obtain the non-differential genes. With the non-differential gene as a target, the non-differential gene can be used for preparing drugs for preventing or treating tumors related to the non-differential gene. Whether the non-differential genes are knocked down for preventing tumors or knocked down after tumors are formed for controlling tumor development, the screened non-differential genes can inhibit the sizes of mice tumors.

The invention discloses a KRAS high-expression cancer vaccine based on recombinant attenuated Listeria monocytogenes and a preparation method and application method thereof. The cancer vaccine is bacterial liquid of an Lm delta actA / plcB-KRAS strain; the Lm delta actA / plcB-KRAS strain is a gene recombinant bacterium carrying a KRAS protein gene by taking the attenuated Listeria monocytogenes asa carrier; the attenuated Listeria monocytogenes is obtained by completely knocking out two virulence genes of actA and plcB from the Listeria monocytogenes; and the KRAS protein gene is a DNA sequence obtained by synthesizing a KRAS protein amino acid sequence after being optimized by a Listeria codon, adding a Hind III restriction enzyme cutting site at the upstream and adding an Xho I restriction enzyme cutting site at the downstream. According to the KRAS high-expression cancer vaccine disclosed by the invention, the attenuated Listeria monocytogenes is used as the carrier, and the specific immune response in a tumor microenvironment is effectively improved by utilizing the characteristic that the Listeria monocytogenes can uniquely grow in a host phagocyte and is a natural T cell immune activation adjuvant, so that the immune tolerance of an organism is broken, and further the development of tumors can be inhibited.

Water soluble compounds having a furoxan structure which are capable of inhibiting metabolic pathways involved in the development of the tumours are provided. The use of such compounds as a medicament in the therapy of the tumours and as an adjuvant in the immunotherapy protocols against neoplasms is also described.

The invention discloses an application of lncRNA (long non-coding ribonucleic acid) SLC25A21-AS1 as a marker of esophageal squamous cell carcinoma. The invention provides application of a substance for detecting the expression quantity of LncRNA SLC25A21-AS1 in at least one of the following functions or preparation of a product with at least one of the following functions: (1) a product for predicting the prognosis state of a patient with esophageal squamous carcinoma; (2) predicting the postoperative recurrence-free survival rate of the esophageal squamous carcinoma patient; (3) predicting the overall survival rate of the esophageal squamous carcinoma patient after operation; (4) predicting the tumor differentiation degree of the esophageal squamous carcinoma patient; experiments prove that the lncRNA SLC25A21-AS1 is used as the lncRNA for promoting tumor development, can influence the progress of esophageal squamous cell carcinoma through multiple ways, and prompts that the lncRNA SLC25A21-AS1 has the multifunctional characteristic, but the expression is reduced under the influence of high fat diet or palmitic acid.

The invention discloses a traditional Chinese medicine capsule for replacing cancer postoperative chemotherapy. The invention relates to an anti-cancer traditional Chinese medicine capsule capable of clearing away heat and toxic materials and reducing or replacing the postoperative chemotherapy course of a cancer patient. The anti-cancer traditional Chinese medicine capsule is prepared from 15%-15.5% of taxus chinensis seeds, 7.5%-7.75% of stichopus japonicus, 7.5%-7.75% of paris polyphylla, 7.5%-7.75% of semen strychni, 7.5%-7.75% of oldenlandia diffusa, 7.5%-7.75% of pangolin scales, 7.5%-7.75% of gecko, 7.5%-7.75% of scorpio, 7.5%-7.75% of centipede, 15%-15.5% of dandelion and 7.5%-7.75% of liquorice. The traditional Chinese medicine composition has the advantages that malignant tumor development can be inhibited in a mode of combating poison with poison, the effect of replacing postoperative chemotherapy is achieved, the immunity of a patient can be improved by curing cancerous cells, and then cancer cells are inhibited and cured by relying on the immunity of the patient.

The invention relates to a grease emulsion capable of resisting fatigue, accelerating physical functions to be quickly recovered, resisting tumors and improving the postoperation immunologic functionof a cancer patient, and application thereof, and belongs to the field of medicines. The grease emulsion is prepared from the following ingredients in parts by weight: 15-20 parts of MCT (Medium ChainTriglyceride), 1-7 parts of soybean oil and 2-7 parts of fish oil. Grease ingredients of the grease emulsion generate an obvious synergistic effect, fatigue can be resisted, the physical functions are quickened to be recovered, tumor development is resisted, and the immunologic function of the patient after a postoperation can be obviously improved.

Rapid, easy and early pancreatic cancer diagnosis and therapeutic follow up continue to necessitate an increasing attention towards the development of effective treatment strategies for this lethal disease. The non-invasive quantitative assessment of pancreatic heterogeneity is limited. Here, the inventors report the development of a preclinical imaging protocol using ultrasonography and shear wave technology in an experimental in situ pancreatic cancer model to measure the evolution of pancreatic rigidity. The inventors evaluated the feasiblity of a live imaging protocol by assessing pancreas evolution with Aixplorer technology across 37 weeks. Protumorigenic mutations induced a significant decrease of the rigidity of pancreatic tissue before tumors developed in correlation with the detection of senescent marker p16-positive cells. Thus the promising results indicate the potential of the shear wave elastography to support individualization of diagnosis in this most aggressive disease. Thus, the present invention relates to methods for determining whether a subject has or is at risk of having a pancreatic cancer by using ultrafast elasticity imaging.

The invention relates to a nano preparation for treating multidrug resistance tumours, a composition and application of the nano preparation and the composition. Tumour drug resistance is a main reason of current clinical chemotherapy failure; and in order to realize a drug resistance tumour reversal effect, the invention provides a nano preparation for drug resistance tumours and a preparation method of the nano preparation, wherein the nano preparation is a pharmaceutical composition of paclitaxel and resveratrol; and the nano preparation with a bionic structure is constructed through a pH-sensitive lipid material and a targeting material. Through verification, the nano preparation has a good entrapment effect and physicochemical properties, and shows good pH responsiveness in in-vitro release. Animal experiments prove that the nano preparation can effectively inhibit the tumour development process, is higher in safety when applied to animal bodies, is expected to be applied to clinical treatment and overcomes the defects of chemical medicine treatment.

The invention discloses a 3D printing device for detecting hydrogen peroxide secreted by cells based on a bipolar electrode-light-emitting diode-photoresistor platform. Based on the characteristics of 3D printing that can realize personalized design and precise printing and the principle that isoelectronic redox reactions can occur at both ends of BPE for analyte detection, combined with the advantages of easy construction of BPE system, cheap and easy to obtain and reusable LED and LDR , constructed the BP‑LED‑E‑LDR platform for human breast cancer cells (MCF‑7) to secrete H 2 o 2 detection. Under optimal conditions, the present invention semi-quantitatively detects the concentration of the analyte in the sample pool through the visualization feature of BP-LED-E, and further quantitatively detects the H secreted by cells through LDR and digital multimeter. 2 o 2 It provides a new idea and a new platform for the preliminary judgment of cell growth and proliferation and tumor development and other related research fields.